**Literature**

s41 Jones SA, Hunter CA. Is IL-6 a key cytokine target for therapy in COVID-19? *Nat Rev Immunol* Published Online First: 2021. doi:10.1038/s41577-021-00553-8


---

Monschein T, et al. *J Neurol Neurosurg Psychiatry* 2021;0:1–11. doi: 10.1136/jnnp-2021-326839


Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. *Nat Med* 2013;19:1597–608. doi:10.1038/nm.3409


Sturkenboom MCJM. The narcolepsy-pandemic influenza story: Can the truth ever be unravelled? *Vaccine* 2015;33:B6–13. doi:10.1016/j.vaccine.2015.03.026

https://www.pei.de/EN/home/home-node.html;jsessionid=3FE08D54F2B7370B15D4F813BAC66950.intranet212.


s146  Chadox F, Simpson CR, Shi T, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Published Online First: Nature medicine 2021. doi:10.1038/s41591-021-01408-4


s151  Mahase E. Covid-19: Unusual blood clots are “very rare side effect” of Janssen vaccine, says EMA. Bmj 2021;n1046. doi:10.1136/bmj.n1046


https://www.msif.org/. 

Monschein T, et al. J Neurol Neurosurg Psychiatry 2021;0:1–11. doi: 10.1136/jnnp-2021-326839


